How GLP-1 analogs are reshaping diabetes care and obesity treatment and unlocking potential in cardiovascular, inflammatory, ...

HealthDay News — Among US adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022, according ...

A new analysis of FDA adverse event reports suggests a potential link between tirzepatide and thyroid cancer. Learn what this ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation involving this class of drugs. Over the past few years ...

The study found that female rodents have nearly double the GLP-1 receptor expression in brain regions linked to nausea. If that result is consistent in humans, it could help explain why women ...

Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from 2022 to 2023. Although spending for certain GLP-1 RAs increased ...

The family of medications called GLP-1 receptor agonists includes drugs like Wegovy, Zepbound, Ozempic, Mounjaro and Victoza. They were originally developed to treat type 2 diabetes, which happens ...

Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new study says.

Phytogene is designed not only for GLP-1 receptor agonists like semaglutide but also for other peptide-based therapeutics.

Biological Mechanisms Identified: The study reveals that female mice have nearly double the GLP-1 receptor expression in brain regions linked to nausea, explaining their heightened side effects.